Arkolith/Insider Trading/KZR/Form 4

Fowler John Franklin

DirectorKezar Life Sciences, Inc. (KZR) · full profile →Form 4 · filed May 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
3 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Tender(U)39K——0
May 11, 2026Tender(U)375——0
May 11, 2026Tender(U)4K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 11, 2026Disposed to issuer(D)5K—$00
May 11, 2026Disposed to issuer(D)18K—$00
May 11, 2026Disposed to issuer(D)9K—$00
May 11, 2026Disposed to issuer(D)22K—$00
May 11, 2026Disposed to issuer(D)5K—$00
May 11, 2026Disposed to issuer(D)5K—$00
May 11, 2026Disposed to issuer(D)17K—$00
May 11, 2026Disposed to issuer(D)20K—$00
May 11, 2026Disposed to issuer(D)120K—$00
May 11, 2026Disposed to issuer(D)50K—$00
May 11, 2026Disposed to issuer(D)58K—$00

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001744263-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML